| Endoscopic Evidence of Maintenance of Healing With Oral NEXIUM in Patients 1 to 11 Years Old With Erosive Esophagitis. (NCT05267613) | AstraZeneca | 2022-07-01 |
| JP-1366 20mg Versus Esomeprazole 40mg in Patients With Erosive Esophagitis (NCT05443984) | Onconic Therapeutics Inc. | 2022-01-17 |
| A Study in Patients With Erosive Esophagitis to Investigate Safety, Tolerability, and Healing Rates After 4 Weeks Treatment of X842 or Lansoprazole and Symptom Pattern During Subsequent 4 Weeks Treatment With Lansoprazole (NCT05055128) | Cinclus Pharma Holding AB | 2021-08-11 |
| A Study to Evaluate the Safety, Tolerability and Pharmacokinetics/Pharmacodynamics of Oral Doses of H008 (NCT05050188) | Jiangsu Carephar Pharmaceutical Co., Ltd. | 2021-06-24 |
| Treatment Effect According to Timing of Administration of DWP14012 40 mg (NCT04888819) | Konkuk University Medical Center | 2021-02-01 |
| Treatment Effect According to Timing of Administration of DWP14012 40 mg (NCT04613895) | Daewoong Pharmaceutical Co. LTD. | 2020-11-17 |
| Real-life Study of Changes of Gastroesophageal Reflux Disease Manifestations Due to Behavioural and Diet Adherence (NCT04255693) | Federal State Budgetary Scientific Institution | 2020-01-31 |
| Efficacy and Safety of Vonoprazan Compared to Lansoprazole in Participants With Erosive Esophagitis (NCT04124926) | Phathom Pharmaceuticals, Inc. | 2019-10-28 |
| Clinical Trial to Assess the Efficacy and Safety of YYD601 in the Treatment of Esophageal Reflux Disease (ERD) (NCT03943992) | Yooyoung Pharmaceutical Co., Ltd. | 2019-01-29 |
| Study to Evaluate the Efficacy and Safety of DWP14012 in Patients With Erosive Gastroesophageal Reflux Disease (Phase 3) (NCT03736369) | Daewoong Pharmaceutical Co. LTD. | 2018-12-13 |
| Confocal Endomicroscopy for Permeability of Esophageal Wall in Refractory Gastroesophageal Reflux Disease (GERD) (NCT03228407) | McGuire Research Institute | 2017-04-28 |
| Efficacy and Safety of Dexlansoprazole in Healing and Maintaining Healing of Erosive Esophagitis (NCT02873702) | Takeda | 2016-12-21 |
| Study to Confirm the Safety and Efficacy of CJ-12420 in Patients With Erosive Esophagitis (NCT03006874) | HK inno.N Corporation | 2016-05-02 |
| Vonoprazan Study in Patients With Erosive Esophagitis to Evaluate Long-term Safety (NCT02679508) | Takeda | 2016-03-20 |
| Study to Evaluate the Safety and Efficacy of CJ-12420 in Patients With Erosive Esophagitis (NCT02456935) | HK inno.N Corporation | 2015-05-01 |
| A Study to Compare the Pharmacokinetic Characteristics of CJ-12420 (NCT02995239) | HK inno.N Corporation | 2015-04-01 |
| Efficacy and Safety of Vonoprazan Compared to Lansoprazole in the Maintenance Treatment of Erosive Esophagitis (NCT02388737) | Takeda | 2015-04-01 |
| Sensory Evaluation of Dexlansoprazole Delayed-Release Orally Disintegrating Tablets (NCT02096458) | Takeda | 2014-02-01 |
| Study to Evaluate the Safety and Efficacy of CJ-12420 in Patients With Erosive Esophagitis (NCT02028663) | HK inno.N Corporation | 2013-05-01 |
| Proton Pump Inhibitor (PPI) Responsive Eosinophilic Esophagitis EoE: Gastroesophageal Reflux Disease (GERD) or Eosinophilic Esophagitis (EoE)? (NCT01865825) | Mayo Clinic | 2013-03-01 |
| Safety and Efficacy of Dexlansoprazole Delayed-Release Capsules for Healing of Erosive Esophagitis and Maintenance of Healed Erosive Esophagitis and Relief of Heartburn in Adolescents (NCT01642615) | Takeda | 2012-07-01 |
| A Randomized, Double-Blind, Multicenter Study to Evaluate the Acid-inhibitory and Dose-response Efficacy of TAK-438 (20 mg, 40 mg) in Patients With Proton Pump Inhibitor (PPI) - Resistant Erosive Esophagitis (NCT01630746) | Takeda | 2012-07-01 |
| A Multi-center, Randomized, Double-blind Phase III Clinical Trial to Assess and Compare to the Efficacy and Safety of Lafutidine, Famotidine and Omeprazole-referenced in Korean Erosive Esophagitis Patients (NCT01499368) | Boryung Pharmaceutical Co., Ltd | 2011-11-01 |
| Efficacy of TAK-438 Compared to AG-1749 (Lansoprazole) in the Maintenance Treatment of Healed Erosive Esophagitis (NCT01459367) | Takeda | 2011-10-01 |
| Long-Term Safety Study of TAK-438 in the Maintenance Treatment of Healed Erosive Esophagitis (NCT01452776) | Takeda | 2011-09-01 |
| Efficacy Study of Ilaprazole to Treat Erosive Esophgitis (NCT01509261) | Il-Yang Pharm. Co., Ltd. | 2010-07-01 |
| Rate of Complete Symptom Relief, Prevention of Symptom Relapse: Grades A and B Esophagitis of Esomeprazole Therapy (NCT01874535) | Chang Gung Memorial Hospital | 2010-06-01 |
| To Learn How Bone Structure and Bone Mass Change After Long-term PPI Use (NCT01306799) | University of Pennsylvania | 2010-01-01 |
| Impact of Timing on the Efficacy of Zegerid 40 mg in Healing Reflux Esophagitis: A Pilot Study (NCT00693225) | Yvonne Romero | 2008-01-01 |
| Proton Pump Inhibitor (PPI) Therapy for Newly Diagnosed Esophagitis (NCT00586963) | Mayo Clinic | 2008-01-01 |
| Esomeprazole for Treatment of GERD in Pediatric Patients (NCT00228527) | AstraZeneca | 2004-10-01 |
| NEXIUM® in the Treatment of Moderate and Severe Erosive Esophagitis (NCT00206180) | AstraZeneca | 2004-06-01 |
| A Multicenter, Randomized, Double Blind, Double Dummy, Parallel-Group Efficacy Study Comparing 8 Weeks of Treatment With Esomeprazole Magnesium (40mg qd) to Lansoprazole (30mg qd) for the Healing of Erosive Esophagitis in Patients With Moderate or Severe Erosive Esophagitis (NCT00641602) | AstraZeneca | 2002-12-01 |
| Multicenter, Randomized, Double-Blind, Double-Dummy, Parallel-Group Comparison of the Remission Rates of Once Daily Treatment With Esomeprazole 20mg and Lansoprazole 15mg for 6 Months in Patients Whose EE Has Been Healed (NCT00644735) | AstraZeneca | 2002-12-01 |
| Efficacy of TAK-438 Compared to AG-1749 (Lansoprazole) in the Treatment of Erosive Esophagitis (NCT01452698) | Takeda | |